抗治療性憂鬱症的市場:各藥物類型，各流通管道，各地區-規模，佔有率，展望，機會分析，2022年～2030年

Treatment Resistant Depression Market, by Drug Type (Antidepressants Atypical agents, others), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年09月02日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場動態

增加無機活動，例如組織資助以擴大其在全球抗治療抑鬱症市場的影響力，預計將在預測期內推動市場增長。

本調查的主要特徵

本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球抗治療性憂鬱症市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球抗治療性憂鬱症市場的主要參與者之企業簡介。
藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球抗治療性憂鬱症市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以透過全球抗治療性憂鬱症市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

熱圖分析
市場佔有率分析
- AbbVie Inc.
- Lupin
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Bausch Health Companies Inc.
- Sanofi
- Mallinckrodt
- Johnson & Johnson
- Merck & Co., Inc.
- Viatris Inc.
- Otsuka Holdings Co., Ltd.
- Lundbeck A/S
- AstraZeneca
- Aurobindo Pharma Ltd.

第9章章節

調查手法的介紹
關於出版社

簡介目錄

Product Code: CMI5196

Depression is a mood disorder that causes a persistent feeling of sadness and a loss of interest. Also called major depressive disorder or clinical depression, it affects how patients feel, think, and behave and can lead to a variety of emotional and physical problems. Patients may have trouble doing normal day-to-day activities. Depression (major depressive disorder) is a common and serious medical illness that negatively affects how patients feel, the way they think, and how they act. Depression causes feelings of sadness and/or a loss of interest in activities patients once enjoyed. It can lead to a variety of emotional and physical problems. There are various drugs available for treatment of depression, such as antidepressants, which are medications that can help relieve symptoms of depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder. The atypical agents, also known as second generation antipsychotics and serotonin-dopamine antagonists, are a group of antipsychotic drugs largely introduced to be used to treat psychiatric conditions.

Market Dynamics

Increasing inorganic activities such as fund raise by organizations in order to expand their presence in the global treatment resistant depression market is expected to drive the market growth over forecast period. For instance, in February 2022, Minded, the specialist in prescribing mental health medication online, announced US$ 25 million in seed funding. Investors included Streamlined Ventures, Link Ventures, The Tiger Fund, Unicorn Ventures, Trousdale Ventures, Gaingels, SALT Fund, TheFund, and the founders of Care.com, Bolt, Gravity Blanket, RXBAR, and Gilt.com, along with venture debt from Western Technology Investment (WTI).

Increasing development of novel therapeutics for the treatment of resistant depression by market players to launch their novel products is expected to drive market growth over forecast period. For instance, in September 2021, XWPharma Ltd., a biopharmaceutical company, announced dosing of subjects in its first-in-human study evaluating XW10508, the company's novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.

Key features of the study:

This report provides an in-depth analysis of the global treatment resistant depression market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global treatment resistant depression market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global treatment resistant depression market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global treatment resistant depression market

Detailed Segmentation:

Global Treatment Resistant Depression Market, by Drug Type :
- Antidepressants
  - Selective Serotonin Reuptake Inhibitors
  - Serotonin-norepinephrine Reuptake Inhibitors
  - Others
- Atypical agents
- Others
Global Treatment Resistant Depression Market, by Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Treatment Resistant Depression Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- AbbVie Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Lupin
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Bausch Health Companies Inc.
- Sanofi
- Mallinckrodt
- Johnson & Johnson
- Merck & Co., Inc.
- Viatris Inc.
- Otsuka Holdings Co., Ltd.
- Lundbeck A/S
- AstraZeneca
- Aurobindo Pharma Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Treatment Resistant Depression Market- Impact of Coronavirus (COVID-19) Pandemic

Impact on Demand
Impact on Healthcare
Epidemiology

5. Global Treatment Resistant Depression Market, By Drug Type, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Selective Serotonin Reuptake Inhibitors
Serotonin-norepinephrine Reuptake Inhibitors
Others
Atypical agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

6. Global Treatment Resistant Depression Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

7. Global Treatment Resistant Depression Market, By Region, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030(%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa